Why the study?
Does a combination of a Gs-biased β2-adrenoceptor agonist and a β1-adrenoceptor antagonist improve outcomes in heart failure compared to traditional therapies?
Population
Heart failure (including animal models)
Comparison
Combination of a Gs-biased β2-adrenoceptor… vs Traditional heart failure therapies
Design
Review
Authors
Loading...
Does not support clinical use; hypothesis-generating for biased β-adrenoceptor targeting in heart failure.
Does a combination of a Gs-biased β2-adrenoceptor agonist and a β1-adrenoceptor antagonist improve outcomes in heart failure compared to traditional therapies?
This review highlights the pathogenic role of Gi-biased β2-adrenoceptor signalling in heart failure and proposes a novel combination therapy targeting Gs-biased β2 and β1 receptors.
Woo et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: